We used Low pressure mercury vapor lamp activated of Sodium Persulfate (UV/SPS) and Fenton processes in two separate reactors to comparison of cephalexin (CPX) degradation in aqueous solution. The effect of pH, initial concentration of SPS, concentration of CPX, concentration of HO and concentration of Fe on the degradation of CPX were investigated. The residue of CPX and metabolites were determined by HPLC and GC/MS. The Total Organic Carbon (TOC) analysis was utilized for surveying the mineralization of CPX. Biodegradability of CPX in both advanced oxidation processes was evaluated by BOD5/COD in optimum condition. The results indicated that the maximum CPX removal was obtained at pH 3, HO 3 mM, concentration of initial CPX 10 mg/L and by increasing the doses of SPS from 0.1 to 0.2 mM, the degradation of CPX was enhanced. In this study, the most important factors for AOP efficiency was concentration of initial CPX; and then pH in UV/SPS and HO in Fenton processes. The TOC measurements indicate that the UV/SPS and Fenton can efficiently mineralize CPX. CPX removed enough to achieve suitable biodegradability for a further biological process. Too, analysis of generated intermediates during the degradation of CPX was conducted by GC/MS method and a degradation pathway was proposed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721770 | PMC |
http://dx.doi.org/10.1007/s40201-020-00553-1 | DOI Listing |
Methods Mol Biol
January 2025
Departments of Neurology, and Anatomy and Cell Biology, Wayne State University School of Medicine, University Health Center, Detroit, MI, USA.
Molecular dynamics (MD) simulations enable in silico investigation of the dynamic behavior of proteins and protein complexes. Here, we describe MD simulations of the SNARE bundle forming the complex with the neuronal proteins Synaptotagmin-1 (Syt1) and Complexin (Cpx). Syt1 is the synaptic vesicle (SV) protein that serves as the neuronal calcium sensor and triggers synaptic fusion upon calcium binding, and this process is promoted and accelerated by Cpx.
View Article and Find Full Text PDFSensors (Basel)
December 2024
Biomedicine Research Center of Strasbourg (CRBS), UR 3072, "Mitochondria, Oxidative Stress and Muscle Plasticity", Faculty of Medicine, University of Strasbourg, 67000 Strasbourg, France.
The continuous monitoring of oxygen saturation (SpO) and respiratory rates (RRs) are major clinical issues in many cardio-respiratory diseases and have been of tremendous importance during the COVID-19 pandemic. The early detection of hypoxemia was crucial since it precedes significant complications, and SpO follow-up allowed early hospital discharge in patients needing oxygen therapy. Nevertheless, fingertip devices showed some practical limitations.
View Article and Find Full Text PDFBackground: Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF).
Aims: This study aimed to characterize patients with exertional dyspnoea and normal/near-to-normal N-terminal pro-brain natriuretic peptide (NT-proBNP) levels with regard to early stages of HFpEF and non-cardiac causes.
Drug Metab Pharmacokinet
November 2024
Drug Metabolism and Pharmacokinetics Research Department, Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Japan.
CPX-351 (NS-87; Vyxeos®) has a characteristic liposomal formulation and contains cytarabine and daunorubicin at a 5:1 molar ratio, which demonstrates synergistic activity in both in vitro and in vivo animal models. It has been approved in several countries for the treatment of newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Since there are very few Asian patients, especially Japanese adult and pediatric patients, only a small clinical study has been conducted in Japanese adult patients and no study in Japanese pediatric patients.
View Article and Find Full Text PDFBr J Haematol
December 2024
Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
This pilot study evaluated CPX-351 in adults with newly diagnosed, favourable-intermediate risk, FLT3-ITD-negative AML. Twenty patients received CPX-351 for induction, with six also receiving gemtuzumab ozogamicin (GO). The complete response rate was 95%, with 42% achieving flow-based minimal residual disease (MRD) negativity post-induction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!